NATALIZUMAB: Algunas Revisiones y artìculos relevantes

PMC Results Items 1 - 20 of 367 1: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells Max-Philipp Stenner, Anne Waschbisch, Dorothea Buck, Sebastian Doerck, Hermann Einsele, Klaus V. Toyka, and Heinz Wiendl PLoS ONE. 2008; 3(10): e3319. Published online 2008 October 6. doi: 10.1371/journal.pone.0003319. PMCID: PMC2553177 | Abstract | Full Text | PDF–271K | Supplementary Material | Correction | 2: Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function B O. Khatri, S Man, G Giovannoni, A P. Koo, J-C Lee, B Tucky, F Lynn, S Jurgensen, J Woodworth, S Goelz, P W. Duda, M A. Panzara, R M. Ransohoff, and R J. Fox Neurology. 2009 February 3; 72(5): 402–409. doi: 10.1212/01.wnl.0000341766.59028.9d. PMCID: PMC2677532 | Abstract | Full Text | PDF–1.6M | Supplementary Material | 3: Natalizumab for the treatment of relapsing multiple sclerosis Richard A Rudick and Michael A Panzara Biologics. 2008 June; 2(2): 189–199. Published online 2008 June. PMCID: PMC2721353 | Abstract | Full Text | PDF–271K | 4: Natalizumab in the Treatment of Multiple Sclerosis Özgür Yaldizli and Norman Putzki Ther Adv Neurol Disord. 2009 March; 2(2): 115–128. doi: 10.1177/1756285608101861. PMCID: PMC3002624 | Abstract | Full Text | PDF–132K | 5: Natalizumab: A new treatment for relapsing remitting multiple sclerosis Michael Hutchinson Ther Clin Risk Manag. 2007 June; 3(2): 259–268. Published online 2007 June. PMCID: PMC1936307 | Abstract | Full Text | PDF–103K | 6: Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells P Kivisäkk, B C. Healy, V Viglietta, F J. Quintana, M A. Hootstein, H L. Weiner, and S J. Khoury Neurology. 2009 June 2; 72(22): 1922–1930. doi: 10.1212/WNL.0b013e3181a8266f. PMCID: PMC2690969 | Abstract | Full Text | PDF–1.1M | Supplementary Material | 7: Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients Karen Yao, Susan Gagnon, Nahid Akhyani, Elizabeth Williams, Julie Fotheringham, Elliot Frohman, Olaf Stuve, Nancy Monson, Michael K. Racke, and Steven Jacobson PLoS ONE. 2008; 3(4): e2028. Published online 2008 April 30. doi: 10.1371/journal.pone.0002028. PMCID: PMC2323568 | Abstract | Full Text | PDF–242K | Supplementary Material | 8: Natalizumab in the treatment of multiple sclerosis Brandon A Brown Ther Clin Risk Manag. 2009; 5: 585–594. Published online 2009 August 3. PMCID: PMC2724189 | Abstract | Full Text | PDF–163K | 9: Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy O Stüve, P D. Cravens, E M. Frohman, J T. Phillips, G M. Remington, G von Geldern, S Cepok, M P. Singh, J W. Cohen Tervaert, M De Baets, D MacManus, D H. Miller, E W. Radü, E M. Cameron, N L. Monson, S Zhang, R Kim, B Hemmer, and M K. Racke Neurology. 2009 February 3; 72(5): 396–401. doi: 10.1212/01.wnl.0000327341.89587.76. PMCID: PMC2677530 | Abstract | Full Text | PDF–806K | Supplementary Material | 10: Natalizumab in the treatment of Crohn's disease Danila Guagnozzi and Renzo Caprilli Biologics. 2008 June; 2(2): 275–284. Published online 2008 June. PMCID: PMC2721358 | Abstract | Full Text | PDF–228K | 11: Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab Halvard Bonig, Annette Wundes, Kai-Hsin Chang, Sylvia Lucas, and Thalia Papayannopoulou Blood. 2008 April 1; 111(7): 3439–3441. Prepublished online 2008 January 14. doi: 10.1182/blood-2007-09-112052. PMCID: PMC2275012 | Abstract | Full Text | 12: An evidence-based review of natalizumab therapy in the management of Crohn's disease Raja GR Edula and Michael F Picco Ther Clin Risk Manag. 2009; 5: 935–942. Published online 2009 November 29. PMCID: PMC2789688 | Abstract | Full Text | PDF–197K | 13: Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report Stefano Sotgiu, Maria R Murrighile, and Gabriela Constantin BMC Neurol. 2010; 10: 84. Published online 2010 September 23. doi: 10.1186/1471-2377-10-84. PMCID: PMC2954970 | Abstract | Full Text | PDF–791K | 14: Anti-adhesion molecule therapy for inflammatory bowel disease Subrata Ghosh and Remo Panaccione Therap Adv Gastroenterol. 2010 July; 3(4): 239–258. doi: 10.1177/1756283X10373176. PMCID: PMC3002582 | Abstract | Full Text | PDF–420K | 15: Natalizumab in pediatric multiple sclerosis patients E. Ann Yeh and Bianca Weinstock-Guttman Ther Adv Neurol Disord. 2010 September; 3(5): 293–299. doi: 10.1177/1756285610381526. PMCID: PMC3002661 | Abstract | Full Text | PDF–90K | 16: Quantitative risk-benefit analysis of natalizumab J P. Thompson, K Noyes, E R. Dorsey, S R. Schwid, and R G. Holloway Neurology. 2008 July 29; 71(5): 357–364. doi: 10.1212/01.wnl.0000319648.65173.7a. PMCID: PMC2676947 | Abstract | Full Text | PDF–960K | 17: Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy Tarek A. Yousry, Eugene O. Major, Caroline Ryschkewitsch, Gary Fahle, Steven Fischer, Jean Hou, Blanche Curfman, Katherine Miszkiel, Nicole Mueller-Lenke, Esther Sanchez, Frederik Barkhof, Ernst-Wilhelm Radue, Hans R. Jäger, and David B. Clifford N Engl J Med. Author manuscript; available in PMC 2007 July 30. PMCID: PMC1934511 Published in final edited form as: N Engl J Med. 2006 March 2; 354(9): 924–933. doi: 10.1056/NEJMoa054693. Manuscript: | Abstract | Full Text | PDF–104K | 18: Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab Athanasia Mouzaki, Maria Koutsokera, Zoe Dervilli, Maria Rodi, Dimitra Kalavrizioti, Nikolaos Dimisianos, Ioannis Matsoukas, and Panagiotis Papathanasopoulos Int J Gen Med. 2010; 3: 313–320. Published online 2010 October 5. doi: 10.2147/IJGM.S13648. PMCID: PMC2962327 | Abstract | Full Text | PDF–799K | 19: GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study A D. Goodman, H Rossman, A Bar-Or, A Miller, D H. Miller, K Schmierer, F Lublin, O Khan, N M. Bormann, M Yang, M A. Panzara, A W. Sandrock, and For the GLANCE Investigators Neurology. 2009 March 3; 72(9): 806–812. doi: 10.1212/01.wnl.0000343880.13764.69. PMCID: PMC2821836 | Abstract | Full Text | PDF–663K | 20: Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report Stylianos Gatzonis and Anna Siatouni J Med Case Reports. 2009; 3: 8955. Published online 2009 August 27. doi: 10.4076/1752-1947-3-8955. PMCID: PMC2827173 | Abstract | Full Text | PDF–326K |